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OBJECTIVES We sought to determine whether routine thrombectomy prior to stent implantation in
diseased saphenous vein grafts (SVGs) and thrombus-containing native coronary arteries
would reduce peri-procedural myonecrosis and subsequently enhance event-free survival.
BACKGROUND Percutaneous coronary intervention in diseased SVGs and thrombotic native coronary arteries
is complicated by a high rate of peri-procedural myocardial infarction (MI). Thrombectomy
prior to intervention may enhance the safety of intervention and improve early and late
outcomes in these high-risk patients.
METHODS At 60 centers in the U.S. and Canada, 797 patients with 839 diseased SVGs or thrombus-
containing native coronary arteries were prospectively randomized to stent implantation with
versus without prior thrombectomy with the X-SIZER device (ev3, Plymouth, Minnesota).
RESULTS Peri-procedural MI occurred in 15.8% of patients assigned to the X-SIZER device compared
with 16.6% of control patients (p  0.77), although the rate of large MI (pre-specified as the
development of new pathologic Q waves or creatine phosphokinase-MB isoenzyme elevation
8  upper limits of normal) was reduced with X-SIZER device use from 9.6% to 5.5%
(multivariate risk ratio 0.35 [95% confidence interval 0.18 to 0.66], p 0.002). Major adverse
cardiac events (cardiac death, MI, or repeat target vessel revascularization) occurred in 16.8%
of X-SIZER patients versus 17.1% of control patients at 30 days (p  0.92), and in 31.3%
of X-SIZER patients versus 28.2% of control patients at 1 year (p  0.35).
CONCLUSIONS Thrombectomy with the X-SIZER device prior to stent implantation in high-risk diseased
SVGs and thrombus-containing native coronary arteries may reduce the extent, but not the
occurrence, of myonecrosis. Early and late event-free survival, however, were not improved by
routine thrombectomy with this device. (J Am Coll Cardiol 2003;42:2007–13) © 2003 by
the American College of Cardiology Foundation
The introduction of coronary stents and adjunctive phar-
macologic agents including thienopyridines and glycopro-
tein (GP) IIb/IIIa receptor inhibitors have improved the
safety profile of percutaneous coronary intervention (PCI)
(1–5). Despite contemporary approaches, however, the rate
of peri-procedural complications remains excessively high
after PCI in friable lesions prone to embolization, including
native coronary arteries with thrombus and diseased saphe-
nous vein grafts (SVGs) (6–8). Mechanical extraction of
soft atherothrombotic material prior to stent implantation
may further enhance the safety and efficacy of PCI in
high-risk lesions. Therefore, we performed a large-scale,
multicenter, prospective, randomized trial to determine the
utility of thrombectomy with the X-SIZER device (ev3,
Plymouth, Minnesota) during PCI.
METHODS
Study population and study protocol. Angiographic in-
clusion criteria required the presence of1 lesion in a native
coronary artery or SVG with a reference vessel diameter
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3.0 mm and a diameter stenosis50% but100%; totally
occluded SVG lesions could be enrolled if successfully
crossed with a guidewire. The presence of angiographic
thrombus as assessed by the investigator was also mandatory
for inclusion of native coronary artery lesions, although not
for SVGs. Patients with multiple lesions in the same or
different vessels were eligible if all lesions met enrollment
criteria. Clinical and angiographic exclusion criteria in-
cluded: recent (24 h) or acute myocardial infarction (MI)
or elevated creatine phosphokinase (CPK)-MB isoenzyme
on the day of the procedure; left ventricular ejection fraction
30% or cardiogenic shock; target lesion was either an
isolated ostial lesion, at the distal SVG anastomosis, within
a SVG6 months old or an arterial bypass graft conduit, or
within a previously stented segment; excessive vessel or
lesion tortuosity or calcification; prior unsuccessful or com-
plicated PCI within 6 months; and current participation in
other investigational protocols. The study was approved by
the institutional review board at each participating center,
and consecutive, eligible patients signed informed, written
consent.
Before the catheterization procedure, patients received
chewable aspirin 325 mg and clopidogrel 300 mg. The
decision to use procedural GP IIb/IIIa inhibitors was left to
Table 1. Baseline Clinical and Angiographic Characteristics
X-SIZER
Prior to Stent
Stent
Alone p Value
Demographic features
Number of patients 400 397
Age (yrs) 66.4  10.3 65.4  12.1 0.54
Range 31–88 30–88 –
Male gender (%) 78.5 79.1 0.86
Diabetes mellitus (%) 31.6 29.5 0.54
Hypertension (%) 68.9 67.5 0.70
Hyperlipidemia (%) 72.4 69.4 0.39
Current cigarette use (%) 19.6 22.6 0.33
Prior myocardial infarction (%) 66.2 62.4 0.29
Prior coronary bypass surgery (%) 77.0 73.6 0.29
Peripheral vascular disease (%) 16.8 17.0 0.99
Cerebrovascular disease (%) 8.6 11.4 0.19
Unstable angina (%) 85.5 88.9 0.17
Left ventricular ejection fraction (%) 49.4  11.8 50.7  11.1 0.15
Angiographic features
Number of target vessels 420 419
Single-vessel disease (%) 22.3 24.9 0.40
Double-vessel disease (%) 18.5 19.5 0.79
Triple-vessel disease (%) 59.1 55.6 0.32
Target lesion
Left anterior descending artery (%) 6.1 9.6 0.07
Left circumflex artery (%) 3.5 3.0 0.69
Right coronary artery (%) 15.7 15.6 0.99
Saphenous vein graft (%) 74.7 71.9 0.38
Core laboratory analysis
TIMI flow (%)
0/1 12.9 10.5 0.46
2 13.4 10.9 0.33
3 73.7 78.6 0.11
Thrombus (%) 70.1 57.7  0.001
Eccentric lesion (%) 36.5 41.0 0.19
ACC/AHA lesion class B2/C (%) 69.1 70.6 0.94
Reference vessel diameter (mm) 3.33  0.74 3.30  0.66 0.94
Minimal luminal diameter (mm) 1.01  0.68 1.10  0.69 0.07
Diameter stenosis (%) 69.9  18.8 66.8  19.2 0.01
Lesion length (mm) 15.1  10.4 15.2  10.0 0.88
ACC  American College of Cardiology; AHA  American Heart Association; TIMI  Thrombolysis In Myocardial
Infarction.
Abbreviations and Acronyms
CPK  creatine phosphokinase
GP  glycoprotein
MACE  major adverse cardiac events
MI  myocardial infarction
PCI  percutaneous coronary intervention
SVG  saphenous vein graft
TIMI  Thrombolysis In Myocardial Infarction
TVR  target vessel revascularization
ULN  upper limit of normal
X-TRACT  X-SIZER for Treatment of Thrombus
and Atherosclerosis in Coronary
Interventions Trial
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the discretion of the operator. Unfractionated heparin was
administered to attain an activated clotting time of 300 s,
or 200 to 300 s if a GP IIb/IIIa inhibitor was administered.
All patients meeting the angiographic enrollment criteria
were randomized after successful wire-crossing of the first
lesion. Randomization was stratified by planned procedural
GP IIb/IIIa inhibitor use to assure balanced distribution of
this variable.
Randomized patients were equally assigned to either
pre-interventional thrombectomy using the X-SIZER de-
vice, followed by PCI (with stent implantation if possible),
or to PCI and stent implantation without thrombectomy.
The X-SIZER thrombectomy system has been previously
described (9,10). In brief, the X-SIZER device consists of a
helical cutter enclosed within a protective housing attached
to a dual bore catheter shaft containing guidewire and
vacuum/extraction lumens. Activation of the handheld con-
troller simultaneously rotates the helical cutter at 2,100
rpm, which entrains and macerates soft atherosclerotic
plaque and thrombus, and opens a channel to a 250 ml
vacuum collection bottle to permit material aspiration. The
device is available with 1.5, 2.0, and 2.3 mm diameter
cutters for vessels of different sizes, and is compatible with
commercial 0.014-inch guidewires. Multiple slow passes
across the lesion are performed until maximal angiographic
improvement is obtained. Upsizing to a larger diameter
catheter was permitted for persistent residual thrombus or
grummous material after use of an undersized device.
Stent selection and decisions regarding pre- and post-
dilation were at the judgment of the operator. “Bail-out”
GP IIb/IIIa inhibitors in patients not pre-treated and
non-study mechanical atherothrombectomy devices were
allowed only in failed cases or for procedural complications.
Distal protection devices were not available during the
enrollment period of this study. Following the procedure,
serial CPK-MB isoenzymes were drawn at least every 8 h
over 24 h. Patients were maintained on aspirin 325 mg
daily, and clopidogrel 75 mg daily for four weeks. Follow-up
was scheduled at 1, 6, and 12 months after discharge.
Data collection and management. Clinical data were
prospectively collected by dedicated research nurses and
verified on-site by independent study monitors. All primary
end point events were adjudicated by an independent
committee blinded to treatment allocation after review of
the original source documentation. A Data Safety and
Monitoring Committee reviewed blinded data after 100,
350, and 550 patients were randomized, each time recom-
mending the study continue without modification. Inde-
pendent core angiographic laboratory analysis was per-
formed as previously described (11) by technicians blinded
to clinical outcomes.
Statistical methods and definitions. Major adverse car-
diac events (MACE) were defined as the composite inci-
dence of cardiac death, MI, or repeat target vessel revascu-
larization (TVR). Myocardial infarction was defined as any
post-procedural CPK-MB rise3 upper limits of normal
(ULN), and was classified as either Q-wave or non–Q-wave
based on whether new pathological Q waves developed in
Table 2. Procedural Results
X-SIZER
Prior to Stent
(n  400)
Stent
Alone
(n  397) p Value
GP IIb/IIIa inhibitor pre-intervention (%) 75.9 76.6 0.80
Stent implanted (%) 98.0 97.2 0.50
Total stent length (mm) 32.1  21.8 31.1  21.4 0.77
Stent implantation pressure (atms) 13.7  3.8 13.8  3.5 0.53
Intra-procedural events
GP IIb/IIIa inhibitor for “bail-out” (%) 0.8 2.3 0.09
GP IIb/IIIa inhibitor for “bail-out” in patients not pre-treated
with GP IIb/IIIa (%)
3.1 9.8 0.06
Atherothrombectomy for “bail-out” (%) 1.5 2.5 0.33
GP IIb/IIIa inhibitor or atherothrombectomy for “bail-out” (%) 2.3 4.8 0.056
Perforation (%) 0.3 1.3 0.12
Acute closure (%) 1.0 0.8 0.99
Post-procedure core angiographic analysis
TIMI flow (%)
0/1 1.8 2.5 0.72
2 2.8 2.4 0.83
3 95.4 95.0 0.87
TIMI flow improvement (baseline to post-intervention) 0.4  1.0 0.3  1.0 0.17
Residual thrombus (%) 3.3 4.0 0.71
Distal emboli (%) 1.0 1.2 0.99
No reflow (%) 0.5 1.2 0.45
Dissection (%) 1.3 0.2 0.12
Minimal luminal diameter (mm) 2.70  0.71 2.73  0.76 0.41
Diameter stenosis (%) 19.8  15.0 18.7  15.6 0.15
GP  glycoprotein; TIMI  Thrombolysis In Myocardial Infarction.
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2 contiguous leads. “Large” MI was pre-specified in the
protocol as the development of Q waves or CPK-MB
elevation to 8  ULN. An additional pre-specified end
point was the ability of the X-SIZER device to prevent
intra-procedural complications as evidenced by a reduced
need for “bail-out” use of GP IIb/IIIa inhibitors or approved
atherothrombectomy devices.
The sample size was selected to demonstrate a reduction
in the 30-day MACE end point from 16% in the control
group to 9% in the treatment group. Using a two-sided test
of binomial proportions, total alpha was 0.05, and allowing
for two interim analyses using an O’Brien-Fleming bound-
ary analysis, 765 randomized patients afforded the study
80% power. Recruitment of approximately 800 patients was
thus planned to accommodate incomplete data ascertain-
ment or follow-up. The nominal significant level alpha for
each test for the primary end point was 0.014 (@350
patients), 0.021 (@550 patients), and 0.030 (@800 patients).
Categorical variables were compared with the likelihood
ratio chi-square test or the Fisher exact test. Continuous
variables are presented as the mean  SD and were
compared with the Wilcoxon two-sample test. The influ-
ence of baseline demographic and angiographic variables on
30-day clinical outcomes was evaluated with logistic regres-
sion using the Wald chi-square test, and the results were
expressed as odds ratios with 95% confidence intervals. All
analyses were by intention to treat unless otherwise stated,
and all p values were two-sided.
RESULTS
Patient population and baseline characteristics. Between
March 2000 and April 2002, 797 patients with 839 vessels
at 60 sites in the U.S. and Canada were randomized and
treated with either the X-SIZER device prior to stent
implantation or stent implantation alone. Baseline demo-
graphic features were well matched between the two groups
(Table 1). The study cohort was elderly, had a high
frequency of diabetes mellitus and prior MI, and predomi-
nantly consisted of patients with unstable angina. Approx-
imately 73% of the lesions were in SVGs, whereas 27% were
in native coronary arteries. Baseline Thrombolysis In Myo-
cardial Infarction (TIMI) flow was abnormal in 24% of
vessels. By core laboratory analysis, thrombus was present in
approximately two-thirds of cases and was more frequent in
X-SIZER randomized patients. Baseline lesion severity was
also slightly greater among patients assigned to the
X-SIZER device.
Procedural results. As seen in Table 2, in patients ran-
domized to the X-SIZER device, a mean of 1.1  0.1
catheters per case were used (with the 1.5, 2.0, and 2.3 mm
diameter catheters selected in 53%, 46%, and 1% of patients,
respectively). GP IIb/IIIa inhibitors were used prophylacti-
cally in three-quarters of patients in both groups, and stents
were implanted in nearly all patients. In patients in whom
GP IIb/IIIa inhibitors were not administered upfront,
bail-out GP IIb/IIIa inhibitors were required more com-
monly in the control arm than in patients pre-treated with
thrombectomy prior to PCI for the development of intra-
procedural complications. The composite requirement for
the “bail-out” usage of either an approved atherothrombec-
tomy device or a GP IIb/IIIa inhibitor was also reduced in
X-SIZER–assigned patients. The rates of final no reflow
and distal thromboemboli were similar between the two
groups, as were the final rates of TIMI-3 flow (Table 2).
30-day outcomes. Composite MACE rates at 30 days
were similar between the two groups, as were the individual
components of the composite end point (Table 3). Al-
though the absolute occurrence of any degree of peri-
procedural myonecrosis was not reduced with thrombec-
tomy, X-SIZER device use before PCI tended to reduce the
extent of MI at all levels, as seen in Figure 1. When
examined categorically, the pre-specified rate of large MI
was reduced by 43% after thrombectomy with the X-SIZER
device, and a strong univariate trend was present for a
reduction in the combined rate of death or large MI. When
differences in baseline characteristics were corrected for by
multivariate analysis, randomization to the X-SIZER device
prior to PCI was an independent predictor of both freedom
Table 3. 30-Day and 1-Year Clinical Outcomes
X-SIZER
Prior to
Stent
(n  400)
Stent
Alone
(n  397)
p
Value
30-day events (%)
Death (all cause) 1.0 0.3 0.37
Cardiac death 1.0 0.3 0.37
MI 15.8 16.6 0.77
Q-wave 1.0 1.3 0.75
Non–Q-wave 14.8 15.4 0.84
CPK-MB 8  ULN 4.5 8.3 0.03
CPK-MB 3 to 8  ULN 10.3 7.1 0.11
Large MI* 5.5 9.6 0.03
Death or large MI* 6.3 9.8 0.07
TLR 0.8 1.3 0.99
TVR not involving the target lesion 0.8 0 0.99
Composite MACE 16.8 17.1 0.92
In saphenous vein grafts 19.6 19.3 0.99
In thrombotic native coronary arteries 9.0 9.3 0.99
1-year events (%)
Death (all cause) 6.5 4.3 0.17
Cardiac death 5.0 3.5 0.38
MI 19.3 18.9 0.93
Q-wave 1.5 1.5 0.99
Non–Q-wave 17.8 17.4 0.93
CPK-MB 8  ULN† 4.5 8.1 0.04
CPK-MB 3 to 8  ULN† 11.3 8.1 0.15
Large MI 6.0 9.6 0.065
Death or large MI 10.3 12.8 0.27
TLR 11.8 8.3 0.13
TVR not involving the target lesion 4.0 1.8 0.09
Composite MACE 31.3 28.2 0.35
*Large MI  Q-wave or CPK-MB 8  ULN; †MB values not present in all
patients at 1-year.
CPK-MB  creatine phosphokinase-MB isoenzyme; MACE  major adverse
cardiac events; MI  myocardial infarction; TLR  target lesion revascularization;
TVR  target vessel revascularization; ULN  upper limits of normal.
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from large MI and survival free from large MI (Table 4).
The protective effect of thrombectomy was present in both
SVGs and native coronary arteries, in patients pre-treated or
not pre-treated with GP IIb/IIIa inhibitors, and was espe-
cially evident in patients with core laboratory confirmed
angiographic evidence of thrombus (Fig. 2).
Outcomes in thrombotic lesions. In thrombotic lesions,
X-SIZER device use reduced the mean post-procedural
peak CPK (160  248 vs. 216  330, p  0.021) and peak
CPK-MB (13  26 vs. 25  80, p  0.067). Any
CPK-MB elevation occurred in 24.7% of patients with
thrombotic lesions treated with the X-SIZER device versus
32.5% of controls (p  0.05). The occurrence of death or
large MI by 30 days in patients with thrombotic lesions was
reduced by 53% with X-SIZER device use before PCI
(4.7% vs. 9.9%, p  0.04).
1-year outcomes. At one year, the overall rates for MACE,
as well as death, Q-wave MI, and TVR were similar in both
groups (Table 3). Although the overall rate of non–Q-wave
MI was not reduced by X-SIZER device use, the incidence
of large non–Q-wave MI remained less frequent in X-
SIZER–treated patients, and trends were present toward
reduction in the rates of large MI and death or large MI.
DISCUSSION
Although the widespread use of stents and GP IIb/IIIa
inhibitors have enhanced the safety of PCI (1–5), patients
requiring intervention in diseased SVGs and thrombotic
lesions in native coronary arteries remain at high risk for
peri-procedural complications (6–8). As evident from the
control arm of the current and recent trials, approximately
20% of patients develop an adverse ischemic event within 30
days after stenting in diseased SVGs (12), a rate that is not
diminished by GP IIb/IIIa inhibitors (3). Although the
occurrence of MI after SVG intervention is reduced with
distal protection catheters (12,13) (which were not available
during the period this study was performed), these devices
cannot be applied to distal vein graft lesions; they are unable
to prevent embolization into side branches of coronary
arteries arising at or between the lesion and device, and their
use has not yet been evaluated in the native coronary
circulation. Thus, an unequivocal clinical need exists for a
device that can safely improve clinical outcomes in high-risk
Figure 1. Cumulative frequency distribution curves of peak post-procedural creatine phosphokinase (CPK)-MB isoenzyme for patients randomized to
thrombectomy with the X-SIZER device (open circles) versus control (closed circles). Each curve shows the percentage of patients whose CPK-MB
elevation (expressed as a multiple of institutional upper limit of normal) exceeds the value on the x-axis.
Table 4. Independent Multivariate Correlates of 30-Day
Adverse Events
Hazard Ratio
(95% Confidence Interval)
p
Value
Large myocardial infarction
Age (per yr) 1.06 (1.02–1.10) 0.0003
Lesion length (per mm) 1.04 (1.02–1.06) 0.0006
Randomization to X-SIZER 0.35 (0.18–0.66) 0.002
Reference vessel diameter (mm) 1.54 (1.04–2.28) 0.03
Death or large myocardial infarction
Age (yr) 1.06 (1.02–1.10) 0.0001
Lesion length (mm) 1.04 (1.02–1.06) 0.0001
Randomization to X-SIZER 0.45 (0.25–0.80) 0.008
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patients with diseased SVGs and native coronary arteries
containing thrombus.
The X-SIZER is an intuitive, simple to use, low-cost
device that is compatible with standard angioplasty equip-
ment. Previous studies have shown that this device is
efficient at removing thrombus and soft or grummous
atherosclerotic material, but it has little effect on fibrocalcific
tissue (9,10). In the current large, prospective, multicenter,
randomized trial, use of the X-SIZER device prior to stent
implantation in diseased SVGs and thrombus-containing
native coronary arteries was safe, with no procedural in-
creases noted in the rates of dissection, acute closure, or
perforation. In addition, several early clinical and angio-
graphic benefits of X-SIZER device use were evident,
including a reduction in intra-procedural complications as
evidenced by a lesser need for bail-out GP IIb/IIIa inhibi-
tors. No final differences were noted, however, in the rates
of no reflow, residual thrombus, distal thromboemboli, or
TIMI-3 flow. Moreover, peri-procedural MI occurred in
approximately 16% of patients in both groups, similar to the
control rates from other comparable studies (12). Enzymatic
quantification suggested, however, that the size of MIs
occurring after PCI in diseased SVGs and thrombotic
native coronary arteries might be reduced with the
X-SIZER device. By multivariate analysis, thrombectomy
with the X-SIZER device resulted in a 64% relative reduc-
tion in the pre-specified 30-day rate of large MI, and a 55%
reduction in the composite end point of death or large MI.
These findings are consistent with the fact that thrombec-
tomy with the X-SIZER device reduces the extent but not
the occurrence of post-PCI myonecrosis.
Unfortunately, despite these early salutary effects, no
major clinical benefits of thrombectomy use were evident in
this trial at one-year follow-up; rates of death, Q-wave MI,
and TVR were similar in patients treated with and without
the X-SIZER device. It might have been expected that the
prevention of large MIs in these high-risk patients would
have been clinically relevant, as earlier studies have demon-
strated that it is the development of Q-wave and large
subendocardial non–Q-wave infarcts that adversely impact
survival after PCI, whereas lesser degrees of myonecrosis
have minimal or no impact on late prognosis (14,15).
Although one of the largest trials of its kind performed to
date, however, the present trial study was underpowered to
detect a late mortality difference with X-SIZER device use
solely as a function of a reduction in large non–Q-wave MI.
Moreover, infarct size, although pre-specified, was a sec-
ondary end point of this study. As such, the ability of the
X-SIZER device to reduce infarct size and consequently
improve late clinical outcomes needs to be demonstrated in
additional prospective studies before such an indication can
be clinically recommended.
By design, SVG lesions with and without thrombus
were enrolled in X-SIZER for Treatment of Thrombus
and Atherosclerosis in Coronary Intervention Trial (X-
TRACT). Consistent with its mechanism of action (9,10),
post-hoc angiographic analysis demonstrated that the
X-SIZER device was most effective when the target lesion
contained thrombus. Although cineangiography frequently
underestimates the prevalence of thrombus in patients with
unstable angina (16,17), angiography is relatively specific for
the diagnosis of thrombus (18,19), and in this study the
morphologic appearance of the lesion provided important
direction into identifying patients who might benefit by
adjunctive use of a thrombectomy catheter. Moreover, in
patients with thrombotic lesions, X-SIZER device use prior
to PCI significantly reduced the occurrence of any myone-
crosis, and markedly lowered the rates of large MI and death
or large MI. Subsequent trials with this device, as well as
clinical use, should likely be limited to thrombotic lesions.
Figure 2. Incidence of large myocardial infarction at 30 days in patients randomized to thrombectomy with the X-SIZER device prior to stenting versus
stenting without thrombectomy, stratified by baseline and procedural variables. Black bars  control; open bars  X-SIZER. Native  native coronary
artery; PCI  percutaneous coronary intervention; RRR  relative risk reduction; SVG  saphenous vein graft.
2012 Stone et al. JACC Vol. 42, No. 11, 2003
Thrombectomy During Coronary Intervention December 3, 2003:2007–13
Clinical implications and future directions. In contrast to
the X-SIZER device in the present study, both balloon
occlusion/aspiration and filter-based distal protection de-
vices during SVG intervention reduced the incidence of
small as well as large MIs (12,13), and should remain the
therapy of choice for eligible SVG lesions. The incidence of
MACE at 30 days after SVG PCI in these trials occurred in
10% of patients. Conversely, 30-day MACE rates after
SVG intervention with thrombectomy devices such as the
X-SIZER device and the AngioJet system (Possis Medical,
Minneapolis, Minnesota) (20) have ranged from 19% to
23%, questioning whether the efficiency of thrombus extrac-
tion with the current devices is sufficient to prevent any
degree of myonecrosis when a sensitive detector such as
CPK-MB 3  ULN is utilized. Whether thrombectomy
in concert with distal protection devices might further
improve outcomes after SVG intervention is of interest, but
requires appropriate investigation. Moreover, despite the
fact that both the X-SIZER device and AngioJet system
clearly extract thrombus (10,20), neither the X-TRACT nor
the Vein Graft AngioJet Study-2 (20) trials have proven
whether thrombectomy devices reduce MACE in situations
where distal protection is impossible (distal SVG lesions) or
unproven (thrombotic native coronary arteries). Additional
clinical studies are required to demonstrate whether the
empirically obvious desire to remove thrombus before PCI
improves event-free survival in these settings.
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APPENDIX
For a list of the names of the investigators, research
coordinators, and institutions participating in X-TRACT,
please see the December 3, 2003, issue of JACC at
www.cardiosource.com/jacc.html.
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